Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13992425 | 1.00 | FUCA1 (0.45) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4303371 | 1.00 | FUCA1 (0.45) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1724302 | 1.00 | FUCA1 (0.45) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1983745 | 1.00 | FUCA1 (0.45) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4304653 | 1.00 | FUCA1 (0.45) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL2339005 | 0.98 | FUCA1 (0.44) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL2348540 | 0.98 | FUCA1 (0.44) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL2542931 | 0.98 | FUCA1 (0.44) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17228289 | 0.95 | POLB (0.46) | FUCA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| Isopropyl Alcohol SCHEMBL29020804 | 0.92 | GRIN2B (0.44) | FUCA1ALDH1A1ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907347-A | Preparation method of (4aS,7aS) -6-benzyl octahydro-1H-pyrrolo [3,4-b ] pyridine | 山东国邦药业有限公司 | 2022-08-16 | — | — | CN | claimed |
| WO-2014097272-A2 | METHOD FOR PRODUCTION OF (S,S)-6-BENZYLOCTAHYDRO-1H-PYRROLO[3,4-B]PYRIDINE, AN INTERMEDIATE OF AZABICYCLO PYRIDINE DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-06-26 | — | — | WO | claimed |
| WO-2012131629-A1 | A PROCESS FOR PREPARATION OF INTERMEDIATE OF MOXIFLOXACIN | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | WO | claimed |
| WO-2009125425-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (S.S)-2.8-DIAZABICYCLO[4.3.0]NONANE | NEULAND LABORATORIES LTD (IN) | 2009-10-15 | — | — | WO | claimed |
| EP-1077979-B1 | METHOD FOR PRODUCING (S,S)-BENZYL-2,8-DIAZABICYCLO 4.3.0]NONANE | BAYER HEALTHCARE AG (DE) | 2005-07-06 | — | — | EP | claimed |
| US-6235908-B1 | PREPARATION OF TARTRATE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-22 | — | — | US | claimed |
| EP-1077979-A1 | METHOD FOR PRODUCING (S,S)-BENZYL-2,8-DIAZABICYCLO 4.3.0]NONANE | BAYER AG (DE) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058532-A1 | METHOD FOR PRODUCING (S,S)-BENZYL-2,8-DIAZABICYCLO[4.3.0]NONANE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-18 | — | — | WO | claimed |
| CN-115093409-A | Method for synthesizing moxifloxacin side chain by continuous hydrodebenzylation in microreactor | 河南新天地药业股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-114907347-A | Preparation method of (4aS,7aS) -6-benzyl octahydro-1H-pyrrolo [3,4-b ] pyridine | 山东国邦药业有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114907347-A | Preparation method of (4aS,7aS) -6-benzyl octahydro-1H-pyrrolo [3,4-b ] pyridine | 山东国邦药业有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114907347-A | Preparation method of (4aS,7aS) -6-benzyl octahydro-1H-pyrrolo [3,4-b ] pyridine | 山东国邦药业有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-107686852-B | Preparation method of moxifloxacin intermediate compound | 上海朴颐化学科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-10370388-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-5480879-A | ANTIBACTERIAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-01-02 | — | — | US | disclosed |
| US-5468742-A | Antibacterial agents, feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0603887-A2 | Bicyclic amine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-06-29 | — | — | EP | disclosed |
| EP-0592868-A1 | Quinolonecarboxylic acids | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| EP-0591808-A1 | Quinolonecarboxylic acids | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0550903-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | AGTR2, AGTR1, BDKRB2 | FUCA1 4450/4885CYP1A2 1905/4885CYP3A4 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.